Episode 22: Varun Sivaram

On this podcast, Thomas Byrne, CEO of CleanCapital, sits down with Varun Sivaram, a thought leader in the clean energy space. This podcast discusses the bestseller’s new book “Taming the Sun”, which outlines the current clean energy landscape, and the advances needed to unleash it.

Besides being a writer, Varun Sivaram is a physicist and Chief Technology Officer at ReNew Power Ventures, a multibillion-dollar renewable energy firm. He is also a senior research scholar at Columbia University, a board member for the Stanford University Energy and Environment Institutes, and an editorial board member for the journal “Global Transitions”. Previously, Varun was a professor at Georgetown University and is a Rhodes and a Truman Scholar. Dr. Sivaram holds a degree from Stanford University and a Ph.D. from St. John’s College, Oxford University.

Transcript

Breast Cancer Drugs 🆕 No Password

Breast cancer treatment has undergone a significant transformation, evolving from broad-spectrum chemotherapy to highly targeted therapies that address specific molecular subtypes. Today, treatment is largely guided by such as hormone receptors (ER/PR) and the human epidermal growth factor receptor 2 (HER2), which allow for a "precision medicine" approach. 1. Hormone (Endocrine) Therapies

Challenges and Opportunities in Metastatic Breast Cancer Treatments breast cancer drugs

Hormone therapies are used for cancers that are hormone receptor-positive (HR+), meaning they use estrogen or progesterone to grow. These drugs either lower hormone levels or block receptors on cancer cells. They block the aromatase enzyme, which is necessary

Drugs like Anastrozole (Arimidex) , Letrozole (Femara), and Exemestane (Aromasin) are primarily for postmenopausal women. They block the aromatase enzyme, which is necessary for making estrogen in the body. 2. Targeted Therapies They block the aromatase enzyme

Targeted drugs recognize specific markers, typically proteins, that help cancer cells grow and spread.

Tamoxifen is a cornerstone of HR+ treatment, approved for both pre- and post-menopausal patients to reduce recurrence risk.

Follow The Experts Only Podcast: